Smoldering Multiple Myeloma

Oncology
7
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
7
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Peptide
133%
+ 4 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
2 programs
2
ElotuzumabPhase 2Monoclonal Antibody
NivolumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02903381Completed8Est. Sep 2021
Novartis
NovartisBASEL, Switzerland
1 program
1
BHQ880Phase 21 trial
Active Trials
NCT01302886Completed41Est. Nov 2013
BioInvent International
1 program
1
BI-505Phase 21 trial
Active Trials
NCT01838369Terminated4Est. Dec 2014
Takeda
TakedaTOKYO, Japan
1 program
1
IxazomibPhase 21 trial
Active Trials
NCT02916771Completed61Est. Jan 2025
IO Biotech
IO BiotechCOPENHAGEN, Denmark
1 program
1
PD-L1 peptidePhase 2Peptide1 trial
Active Trials
NCT03850522Terminated6Est. Mar 2021
Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT05597345RecruitingEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Karyopharm TherapeuticsSelinexor
IO BiotechPD-L1 peptide
Bristol Myers SquibbNivolumab
TakedaIxazomib
BioInvent InternationalBI-505
NovartisBHQ880

Clinical Trials (6)

Total enrollment: 120 patients across 6 trials

NCT05597345Karyopharm TherapeuticsSelinexor

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Start: Aug 2023Est. completion: Dec 2025
Phase 2Recruiting
NCT03850522IO BiotechPD-L1 peptide

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Start: Feb 2019Est. completion: Mar 20216 patients
Phase 2Terminated
NCT02903381Bristol Myers SquibbNivolumab

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Start: Oct 2016Est. completion: Sep 20218 patients
Phase 2Completed
NCT02916771TakedaIxazomib

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Start: Oct 2016Est. completion: Jan 202561 patients
Phase 2Completed
NCT01838369BioInvent InternationalBI-505

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Start: Mar 2013Est. completion: Dec 20144 patients
Phase 2Terminated
NCT01302886NovartisBHQ880

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Start: May 2011Est. completion: Nov 201341 patients
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 120 patients
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)